Two years and $78M later, Amgen washes its hands of Advaxis' I/O drug — and shares plummet
Advaxis has taken its investors on a bit of a roller coaster ride this year.
The FDA slapped a clinical hold on a combo study of its lead drug axalimogene filolisbac and AstraZeneca’s Imfinzi in wake of a patient death, which resolved months later after a C-suite overhaul. Late Wednesday, the New Jersey biotech added to the drama by quietly disclosing that Amgen has dropped their $540 million immunotherapy pact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
